依达拉奉右莰醇治疗缺血性脑卒中的研究进展  

Research Progress of Edaravone Dexborneol in the Treatment of Ischemic Stroke

作　　者：席娅琳 汪临华 鹿树军[1] XI Yalin;WANG Linhua;LU Shujun(Department of Neurology,Binzhou Medical University Hospital,Binzhou 256600,China;不详)

机构地区：[1]滨州医学院附属医院神经内科,山东滨州256600

出　　处：《中国医学创新》2024年第10期179-183,共5页Medical Innovation of China

摘　　要：缺血性脑卒中是脑血管疾病中的常见病,严重可导致高级认知及运动障碍,甚至死亡。缺血性脑卒中的治疗方法主要包括早期溶栓和保护神经细胞等治疗,然而目前神经保护剂的临床疗效有待考证,大多数神经保护剂仍未得出有益的证据。新型双靶点复合型神经保护剂依达拉奉右莰醇(ED)可抑制诱导型一氧化氮合酶(iNOS)和肿瘤坏死因子-α(TNF-α)的表达,降低自由基过氧化亚硝基阴离子(ONOO-)水平,从而改善缺血性脑卒中所致的神经损伤症状、功能障碍及活动障碍,本文将对ED的作用机制及其应用发展做一综述,并对ED的临床应用进行展望,为后续的用药提供指导。Ischemic stroke is a common type of cerebrovascular disease that can lead to advanced cognitive and motor deficits and even death.The treatment of ischemic stroke mainly includes early thrombolysis and neuroprotection.However,the clinical efficacy of neuroprotective agents remains to be verified,and most neuroprotective agents have not yet received useful evidence.Edaravone Dexborneol(ED),a new dual-target neuroprotective agent,can inhibit the expression of inducible nitric oxide synthase(iNOS)and tumor necrosis factor-α(TNF-α),reduce the level of peroxynitrite anion(ONOO-),and improve the symptoms of nerve injury,dysfunction,and activity disorder caused by ischemic stroke.This article will review the mechanism of ED and its application development,and prospect the clinical application of ED,so as to provide guidance for subsequent medication.

关 键 词：缺血性脑卒中 自由基清除剂 神经保护剂 依达拉奉右莰醇 

分 类 号：R743.3[医药卫生—神经病学与精神病学]